@article{Kennedy_N-2020_11976, title = {British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic}, author = {Kennedy, N. and Jones, G. and Lamb, Christopher A. and Appleby, R. and Arnott, I. and Beattie, R. and Bloom, S. and Brooks, A. and Cooney, R. and Dart, R. and Edwards, C. and Fraser, A. and Gaya, D. and Ghosh, S. and Greveson, K. and Hansen, R. and Hart, A. and Hawthorne, A. and Hayee, B. and Limdi, J. and Murray, C. and Parkes, G. and Parkes, M. and Patel, K. and Pollok, R. and Powell, N. and Probert, C. and Raine, T. and Sebastian, S. and Selinger, C. and Smith, P. and Stansfield, C. and Younge, L. and Lindsay, J. and Irving, P. and Lees, C.}, month = {jun}, year = {2020}, abstract = {The COVID-19 pandemic is putting unprecedented pressures on healthcare systems globally. Early insights have been made possible by rapid sharing of data from China and Italy. In the UK, we have rapidly mobilised inflammatory bowel disease (IBD) centres in order that preparations can be made to protect our patients and the clinical services they rely on. This is a novel coronavirus; much is unknown as to how it will affect people with IBD. We also lack information about the impact of different immunosuppressive medications. To address this uncertainty, the British Society of Gastroenterology (BSG) COVID-19 IBD Working Group has used the best available data and expert opinion to generate a risk grid that groups patients into highest, moderate and lowest risk categories. This grid allows patients to be instructed to follow the UK government’s advice for shielding, stringent and standard advice regarding social distancing, respectively. Further considerations are given to service provision, medical and surgical therapy, endoscopy, imaging and clinical trials.}, pages = {984-990}, volume = {69}, issue = {6}, journal = {Gut}, publisher = {BMJ Publishing Group}, url = {http://dx.doi.org/10.1136/gutjnl-2020-321244}, }